188 related articles for article (PubMed ID: 24079321)
1. [New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
Brasso K; Thomsen FB; Berg KD; Røder MA; Iversen P
Ugeskr Laeger; 2013 Sep; 175(40):2328-32. PubMed ID: 24079321
[TBL] [Abstract][Full Text] [Related]
2. [Pathophysiology and therapy of castration-resistant prostate cancer].
Merseburger AS; Kuczyk MA; Wolff JM
Urologe A; 2013 Feb; 52(2):219-25. PubMed ID: 23160609
[TBL] [Abstract][Full Text] [Related]
3. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD; Taplin ME
Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide for the treatment of castration-resistant prostate cancer.
Ha YS; Goodin S; DiPaola RS; Kim IY
Drugs Today (Barc); 2013 Jan; 49(1):7-13. PubMed ID: 23362491
[TBL] [Abstract][Full Text] [Related]
5. Changing therapeutic paradigms in castrate-resistant prostate cancer.
Zivi A; Massard C; De-Bono J
Clin Genitourin Cancer; 2010 Dec; 8(1):17-22. PubMed ID: 21208851
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
7. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
[TBL] [Abstract][Full Text] [Related]
9. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
10. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
[TBL] [Abstract][Full Text] [Related]
11. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
12. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
[No Abstract] [Full Text] [Related]
13. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Gupta E; Guthrie T; Tan W
BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
[TBL] [Abstract][Full Text] [Related]
14. Targeting the androgen receptor.
Friedlander TW; Ryan CJ
Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer-from steroid transformations to clinical translation.
Chang KH; Sharifi N
Nat Rev Urol; 2012 Dec; 9(12):721-4. PubMed ID: 23027067
[TBL] [Abstract][Full Text] [Related]
16. First-line abiraterone improves survival in prostate cancer.
Brower V
Lancet Oncol; 2017 Jul; 18(7):e374. PubMed ID: 28602778
[No Abstract] [Full Text] [Related]
17. Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.
Mansourian M; Ghasemi Ms K; Khorsandi PhD D; Vaseghi G
Am J Ther; 2020; 27(5):e541-e543. PubMed ID: 31107252
[No Abstract] [Full Text] [Related]
18. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
Pal SK; Twardowski P; Josephson DY
Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987
[TBL] [Abstract][Full Text] [Related]
19. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
20. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
